Search
for
Sort by
Research 541–570 of 1000+
- 11α-Hydroxyprogesterone, a potent 11β-hydroxysteroid dehydrogenase inhibitor, is metabolised by steroid-5α-reductase and cytochrome P450 17α-hydroxylase/17,20-lyase to produce C11α-derivatives of 21-deoxycortisol and 11-hydroxyandrostenedione in vitro
- 5-Alpha Reductase Inhibitors in Prostate Cancer: From Clinical Trials to Clinical Practice
- Pharmacodynamic modeling of finasteride, a 5 alpha-reductase inhibitor.
- Analysis of breast health outcomes in women on oral 5-alpha reductase inhibitors: A single-center retrospective cohort study
- Evolution, classification, structure, and functional diversification of steroid 5α-reductase family in eukaryotes
- Upregulation of mir-1199-5p is associated with reduced type 2 5-α reductase expression in benign prostatic hyperplasia
- Efficacy and Tolerability of 6-Month Treatment with Tamsulosin Plus the Hexanic Extract of Serenoa repens versus Tamsulosin Plus 5-Alpha-Reductase Inhibitors for Moderate-to-Severe LUTS-BPH Patients: Results of a Paired Matched Clinical Study
- The Risk of Venous Thromboembolism (VTE) in Men with Benign Prostatic Hyperplasia Treated with 5-Alpha Reductase Inhibitors (5ARIs).
- Sexual Dysfunctions Related to Drugs Used in the Management of Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia: A Narrative Review on α-Blockers and 5-Alpha Reductase Inhibitors
- Macular Abnormalities Associated With 5α-Reductase Inhibitor
- Risk of rhabdomyolysis from 5-α reductase inhibitors
- Long-term efficacy and safety of the dual 5-alpha reductase blocker dutasteride on male androgenetic alopecia patients
- Side Effects Related to 5 α-Reductase Inhibitor Treatment of Hair Loss in Women: A Review.
- Steroid 5α-reductase inhibition by polymethoxyflavones
- Three Considerations Before Advising 5-α-Reductase Inhibitors for Chemoprevention
- Long-Term Experience With 5-alpha-Reductase Inhibitors.
- Effect of MK-386, a novel inhibitor of type 1 5 alpha-reductase, alone and in combination with finasteride, on serum dihydrotestosterone concentrations in men.
- 5-Alpha-Reductase Inhibitors Reduce Remission Time of COVID-19: Results From a Randomized Double Blind Placebo Controlled Interventional Trial in 130 SARS-CoV-2 Positive Men
- Effects of 5‐alpha reductase inhibitors on lung function: A reason for discontinuation duringCOVID‐19 pandemic?
- Homology Modeling of 5-alpha-Reductase 2 Using Available Experimental Data
- Synthesis and in vitro study of 17β-[N-ureylene-N,N′-disubstituted]-4-methyl-4-aza-5α-androstan-3-ones as selective inhibitors of type I 5α-reductase
- Pathogenetic justification of the use of 5-alpha reductase inhibitors in the treatment of benign prostatic hyperplasia.
- The connection of 5-alpha reductase inhibitors to the development of depression
- Structure of human steroid 5α-reductase 2 with anti-androgen drug finasteride
- Possible role of 5-alpha reductase inhibitors in non-invasive bladder urothelial neoplasm: multicentre study
- Risk of Depression after 5 Alpha Reductase Inhibitor Medication: Meta-Analysis
- 5-alpha Reductase inhibitors and risk of male breast cancer: a systematic review and meta-analysis
- Intraethnic variation in steroid-5-alpha-reductase polymorphisms in prostate cancer patients: a potential factor implicated in 5-alpha-reductase inhibitor treatment
- A 5α-reductase inhibitor, finasteride, increases differentiation and proliferation of embryonal carcinoma cell-derived-neural cells
- Theoretical Evaluation of Twenty-Cannabinoid Derivatives on Either Androgen Receptor or 5α-Reductase Enzyme